2022 ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2022-09-23±³À°ÀÏÀÚ : 2022-09-23
±³À°Àå¼Ò : ¼Ò³ë Æ縮ü ÄÁº¥¼Ç
±³À°ÁÖÁ¦ :
2022 ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-23 ROOM A 14:00~14:30 Individualized treatment for hemophilia ÇÑÁ¤¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-23 ROOM A 14:30~15:00 Coagulation factor biology ¹ÚÁö°æ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-23 ROOM A 15:00~15:30 Non-factor therapy À¯±â¿µ(Çѱ¹Ç÷¿ìÀç´Ü)
±³À°½Ã°£ 09-23 ROOM A 15:30~16:00 Advances in VWD(von Willebrand Disease) diagnosis and treatment ÇÑÀçÁØ(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-23 ROOM A 16:20~16:50 Recent issues for factor assay in hemophilia treatment ¹Ú¿µ½Ç(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-23 ROOM A 16:50~17:20 Laboratory assay for modified EHL(Extended Half Life) agents and Hemlibra ¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-23 ROOM A 17:20~17:50 Experiences in diagnosis of contact activation system deficiency ±èÇö°æ(¼¿ïÀÇ´ë)